Advertisement

Mifepristone for Postcoital Contraception

  • Archil Khomasuridze
Chapter
Part of the Reproductive Medicine for Clinicians book series (REMECL, volume 1)

Abstract

When in the early 1980s of the last century, Dr. Etienne-Emile Baulieu synthesized the first in the history—antiprogesterone—RU 486 or mifepristone, everybody considered it to be an “abortion pill” only. Beyond any doubt, it was a great achievement too, but the life has showed later that the new compound has not only this possibility but also the potential for solution of all problems, when progesterone is not needed.

References

  1. 1.
    von Hertzen H, et al. Lancet. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. 2002;360(9348):1803–10.Google Scholar
  2. 2.
    Trussell J, Raymond E, Cleland K. Emergency contraception: a last chance to prevent unwanted pregnancy. Princeton: Princeton University; 2016.Google Scholar
  3. 3.
    Wertheimer R. Emergency postcoital contraception. Am FamPhysician. 2000;62(10):2287–92.Google Scholar
  4. 4.
    Sarkar NN. The potential of mifepristone (RU-486) as an emergency contraceptive drug. Acta Obstet Gynecol Scand. 2005;84(4):306–16.CrossRefGoogle Scholar
  5. 5.
    Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med. 2016;374:843–52.CrossRefGoogle Scholar
  6. 6.
    Li HWR, Lo SST, Ng EHY, Ho PC. Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation. Hum Reprod. 2016;31:1200–7.CrossRefGoogle Scholar
  7. 7.
    Cheng L, Che Y, Gülmezglu AM. Interventions for emergency contraception. Cochrane Database Sys Rev. 2012;(8):CD001324.Google Scholar
  8. 8.
    Turok DT, Sanders JN, Thompson IS, Royer PA, Eggebroten J, Gawron L. Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study. Contraception. 2016;93:526–32.CrossRefGoogle Scholar
  9. 9.
    Kapp N, Abitbol JL, Mathé H, Scherrer B, Guilard H, Gainer E, Ulmann A. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception. 2015;91(2):97–104.CrossRefGoogle Scholar
  10. 10.
    United States Food and Drug Administration. FDA communication on levonorgestrel emergency contraceptive effectiveness and weight. Available at: http://www.fda.gov/Drugs/DrugsSafety/PostmarketDrugSafetyinformationforPatientaandProviders/ucm109775.htm. Accessed 24 May 2016.
  11. 11.
    Berger C, Boggavarapu NR, Menezes J, Lalitkumar PG, Gemzell-Danielson K. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Hum Reprod. 2015;30:800–11.CrossRefGoogle Scholar
  12. 12.
    Jasam C, Cochon L, Salvatierra AM, Williams A, Kapp N, Levy-Gompel D, Brache VA. prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception. 2016;93:310–6.CrossRefGoogle Scholar
  13. 13.
    Jatlaoui TV, Riley H, Curtis KM. Safety data for levonorgestrel, ulipristal acetate and Yuzpe regimens for emergency contraception. Contraception. 2016;93:93–212.CrossRefGoogle Scholar
  14. 14.
    Cameron ST, Berger C, Michie L, Klipping C, Gemzell-Danielsson K. The effects on ovarian activity of ulipristal acetate when ‘quickstarting’ a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod. 2015;30:1566–73.CrossRefGoogle Scholar
  15. 15.
    Cintia L, Johansen MS. The effect of plan B on teen abortions: evidence from the 2006 FDA ruling. Contemp Econ Policy. 2015;33:418–33.CrossRefGoogle Scholar
  16. 16.
    Bullock H, Steele S, Kurata N, et al. Pharmacy access to ulipristal acetate in Hawaii: is a prescription enough? Contraception. 2015;92:388–9.CrossRefGoogle Scholar

Copyright information

© IAHR (International Academy of Human Reproduction) 2018

Authors and Affiliations

  • Archil Khomasuridze
    • 1
  1. 1.Georgian Association of Reproductive HealthTbilisiGeorgia

Personalised recommendations